Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Nivolumab (BMS-936558)

6 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    ECOGTHOEA5142

    11/08/2016

    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non- Small Cell Lung Cancers

    Treatment

    ECOGHEME4412

    08/18/2016

    A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

    Treatment

    ECOGMELEA6141

    05/10/2016

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    VICCHEM13105

    04/09/2014

    A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)


    Print this page for your doctor